Physician profile
John M Loeb
NPI 1932106390
$713.41
in general payments reported to CMS, 2019-2025
14 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $522 · 2020: $192.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $268.91 | 2019-2020 | |
| Horizon Therapeutics Plc | $72.82 | 2019-2020 | |
| Pfizer INC. | $71.62 | 2019-2020 | |
| Glaxosmithkline, LLC. | $53.48 | 2019-2020 | |
| Sobi, INC | $35.43 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $34.06 | 2019-2020 | |
| Abbvie INC. | $32.25 | 2019 | |
| Medexus Pharma, INC. | $24.59 | 2019 | |
| Ucb, INC. | $22.99 | 2019 | |
| Alexion Pharmaceuticals, INC. | $22.81 | 2019 | |
| Gilead Sciences, INC. | $19.78 | 2020 | |
| Janssen Biotech, INC. | $18.91 | 2019 | |
| Hikma Pharmaceuticals USA | $18.48 | 2020 | |
| Novartis Pharmaceuticals Corporation | $17.28 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Loeb listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.